Terms: = Prostate cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393 AND Prognosis
126 results:
1. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
2. The Value of Combined Detection of Serum PSA, MALAT1 and tmprss2-ETV1 in Evaluating the Progress and prognosis of prostate cancer.
Zhao G; Pan Z; Wang P
Arch Esp Urol; 2023 Oct; 76(8):555-562. PubMed ID: 37960954
[TBL] [Abstract] [Full Text] [Related]
3. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
Ma T; Jin L; Bai S; Liu Z; Wang S; Shen B; Cho Y; Cao S; Sun MJS; Fazli L; Zhang D; Wedderburn C; Zhang DY; Mugon G; Ungerleider N; Baddoo M; Zhang K; Schiavone LH; Burkhardt BR; Fan J; You Z; Flemington EK; Dong X; Dong Y
J Natl Cancer Inst; 2024 Mar; 116(3):421-433. PubMed ID: 37847647
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
5. Determination of tmprss2-ERG, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract] [Full Text] [Related]
6.
Kobelyatskaya AA; Kudryavtsev AA; Kudryavtseva AV; Snezhkina AV; Fedorova MS; Kalinin DV; Pavlov VS; Guvatova ZG; Naberezhnev PA; Nyushko KM; Alekseev BY; Krasnov GS; Bulavkina EV; Pudova EA
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232996
[TBL] [Abstract] [Full Text] [Related]
7. Differences in prostate cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.
Bell PD; Huber AR; Agostini-Vulaj D
Diagn Pathol; 2021 Apr; 16(1):35. PubMed ID: 33892760
[TBL] [Abstract] [Full Text] [Related]
9. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer.
Marx A; Koopmann L; Höflmayer D; Büscheck F; Hube-Magg C; Steurer S; Eichenauer T; Clauditz TS; Wilczak W; Simon R; Sauter G; Izbicki JR; Huland H; Heinzer H; Graefen M; Haese A; Schlomm T; Bernreuther C; Lebok P; Bonk S
Cancer Biol Med; 2021 Feb; 18(1):245-255. PubMed ID: 33628598
[TBL] [Abstract] [Full Text] [Related]
10. Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets.
Spethmann T; Böckelmann LC; Labitzky V; Ahlers AK; Schröder-Schwarz J; Bonk S; Simon R; Sauter G; Huland H; Kypta R; Schumacher U; Lange T
Mol Oncol; 2021 Jul; 15(7):1956-1969. PubMed ID: 33533127
[TBL] [Abstract] [Full Text] [Related]
11. Genetic Susceptibility of ACE2 and tmprss2 in Six Common cancers and Possible Impacts on COVID-19.
Hoang T; Nguyen TQ; Tran TTA
Cancer Res Treat; 2021 Jul; 53(3):650-656. PubMed ID: 33421977
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive analysis of two potential novel SARS-CoV-2 entries, tmprss2 and IFITM3, in healthy individuals and cancer patients.
Dai YJ; Zhang WN; Wang WD; He SY; Liang CC; Wang DW
Int J Biol Sci; 2020; 16(15):3028-3036. PubMed ID: 33061814
[TBL] [Abstract] [Full Text] [Related]
13. Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.
Möller K; Kluth M; Ahmed M; Burkhardt L; Möller-Koop C; Büscheck F; Weidemann S; Tsourlakis MC; Minner S; Heinzer H; Huland H; Graefen M; Sauter G; Schlomm T; Dum D; Simon R
Int J Cancer; 2021 Feb; 148(3):748-758. PubMed ID: 33045100
[TBL] [Abstract] [Full Text] [Related]
14. High B7-H3 expression is linked to increased risk of prostate cancer progression.
Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
[TBL] [Abstract] [Full Text] [Related]
15. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in prostate cancers Lacking tmprss2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract] [Full Text] [Related]
16. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
[TBL] [Abstract] [Full Text] [Related]
17. Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers.
Marx A; Schumann A; Höflmayer D; Bady E; Hube-Magg C; Möller K; Tsourlakis MC; Steurer S; Büscheck F; Eichenauer T; Clauditz TS; Graefen M; Simon R; Sauter G; Izbicki JR; Huland H; Heinzer H; Haese A; Schlomm T; Bernreuther C; Lebok P; Polonski A
Sci Rep; 2020 Jun; 10(1):8916. PubMed ID: 32488048
[TBL] [Abstract] [Full Text] [Related]
18. Image analysis discloses differences in nuclear parameters between ERG+ and ERG- prostatic carcinomas.
Okoń K; Dyduch G; Białas MB; Milian-Ciesielska K; Szpor J; Leszczyńska I; Tyrak K; Szopiński T; Chłosta P
Pol J Pathol; 2020; 71(1):20-29. PubMed ID: 32429651
[TBL] [Abstract] [Full Text] [Related]
19. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in tmprss2:ERG fusion-negative prostate cancers.
Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
[TBL] [Abstract] [Full Text] [Related]
20. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor prognosis in prostate cancer.
Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
[TBL] [Abstract] [Full Text] [Related]
[Next]
